Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for Anti-TSE Compounds?
Identifieur interne : 002D65 ( Main/Exploration ); précédent : 002D64; suivant : 002D66Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for Anti-TSE Compounds?
Auteurs : B. Caughey [États-Unis] ; W. S. Caughey [États-Unis] ; D. A. Kocisko [États-Unis] ; K. S. Lee [États-Unis] ; J. R. Silveira [États-Unis] ; J. D. Morrey [États-Unis]Source :
- Accounts of Chemical Research [ 0001-4842 ] ; 2006.
Abstract
No validated treatments exist for transmissible spongiform encephalopathies (TSEs or prion diseases) in humans or livestock. The search for TSE therapeutics is complicated by persistent uncertainties about the nature of mammalian prions and their pathogenic mechanisms. In pursuit of anti-TSE drugs, we and others have focused primarily on blocking conversion of normal prion protein, PrPC, to the TSE-associated isoform, PrPSc. Recently developed high-throughput screens have hastened the identification of new inhibitors with strong in vivo anti-TSE activities such as porphyrins, phthalocyanines, and phosphorthioated oligonucleotides. New routes of administration have enhanced beneficial effects against established brain infections. Several different classes of TSE inhibitors share structural similarities, compete for the same site(s) on PrPC, and induce the clustering and internalization of PrPC from the cell surface. These activities may represent a common mechanism of action for these anti-TSE compounds.
Url:
DOI: 10.1021/ar050068p
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002228
- to stream Istex, to step Curation: 002228
- to stream Istex, to step Checkpoint: 000940
- to stream Main, to step Merge: 002D95
- to stream Main, to step Curation: 002D65
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for Anti-TSE Compounds?</title><author><name sortKey="Caughey, B" sort="Caughey, B" uniqKey="Caughey B" first="B." last="Caughey">B. Caughey</name></author><author><name sortKey="Caughey, W S" sort="Caughey, W S" uniqKey="Caughey W" first="W. S." last="Caughey">W. S. Caughey</name></author><author><name sortKey="Kocisko, D A" sort="Kocisko, D A" uniqKey="Kocisko D" first="D. A." last="Kocisko">D. A. Kocisko</name></author><author><name sortKey="Lee, K S" sort="Lee, K S" uniqKey="Lee K" first="K. S." last="Lee">K. S. Lee</name></author><author><name sortKey="Silveira, J R" sort="Silveira, J R" uniqKey="Silveira J" first="J. R." last="Silveira">J. R. Silveira</name></author><author><name sortKey="Morrey, J D" sort="Morrey, J D" uniqKey="Morrey J" first="J. D." last="Morrey">J. D. Morrey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D9570AA45CF61601F20362B4B3A0592330E2FCCE</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1021/ar050068p</idno><idno type="url">https://api.istex.fr/ark:/67375/TPS-M5BVJGWB-R/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002228</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002228</idno><idno type="wicri:Area/Istex/Curation">002228</idno><idno type="wicri:Area/Istex/Checkpoint">000940</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000940</idno><idno type="wicri:doubleKey">0001-4842:2006:Caughey B:prions:and:transmissible</idno><idno type="wicri:Area/Main/Merge">002D95</idno><idno type="wicri:Area/Main/Curation">002D65</idno><idno type="wicri:Area/Main/Exploration">002D65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Prions and Transmissible
Spongiform Encephalopathy
(TSE) Chemotherapeutics: A
Common Mechanism for Anti-TSE
Compounds?</title><author><name sortKey="Caughey, B" sort="Caughey, B" uniqKey="Caughey B" first="B." last="Caughey">B. Caughey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Montana</region></placeName><wicri:cityArea> Corresponding author. Mailing address: Rocky Mountain Labs, 903S. 4th St., Hamilton</wicri:cityArea></affiliation></author><author><name sortKey="Caughey, W S" sort="Caughey, W S" uniqKey="Caughey W" first="W. S." last="Caughey">W. S. Caughey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Kocisko, D A" sort="Kocisko, D A" uniqKey="Kocisko D" first="D. A." last="Kocisko">D. A. Kocisko</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Lee, K S" sort="Lee, K S" uniqKey="Lee K" first="K. S." last="Lee">K. S. Lee</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Silveira, J R" sort="Silveira, J R" uniqKey="Silveira J" first="J. R." last="Silveira">J. R. Silveira</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation></author><author><name sortKey="Morrey, J D" sort="Morrey, J D" uniqKey="Morrey J" first="J. D." last="Morrey">J. D. Morrey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases,National Institutes of Health, Rocky Mountain Laboratories,Hamilton, Montana, and Institute for Antiviral Research,Animal, Dairy and Veterinary Sciences Department, UtahState University, Logan</wicri:cityArea></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Accounts of Chemical Research</title><title level="j" type="abbrev">Acc. Chem. Res.</title><idno type="ISSN">0001-4842</idno><idno type="eISSN">1520-4898</idno><imprint><publisher>American Chemical Society</publisher><date type="e-published">2006</date><date type="published">2006</date><biblScope unit="vol">39</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="646">646</biblScope><biblScope unit="page" to="653">653</biblScope></imprint><idno type="ISSN">0001-4842</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-4842</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">No validated treatments exist for transmissible spongiform encephalopathies (TSEs or prion diseases) in humans or livestock. The search for TSE therapeutics is complicated by persistent uncertainties about the nature of mammalian prions and their pathogenic mechanisms. In pursuit of anti-TSE drugs, we and others have focused primarily on blocking conversion of normal prion protein, PrPC, to the TSE-associated isoform, PrPSc. Recently developed high-throughput screens have hastened the identification of new inhibitors with strong in vivo anti-TSE activities such as porphyrins, phthalocyanines, and phosphorthioated oligonucleotides. New routes of administration have enhanced beneficial effects against established brain infections. Several different classes of TSE inhibitors share structural similarities, compete for the same site(s) on PrPC, and induce the clustering and internalization of PrPC from the cell surface. These activities may represent a common mechanism of action for these anti-TSE compounds.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Montana</li><li>Utah</li></region></list><tree><country name="États-Unis"><region name="Utah"><name sortKey="Caughey, B" sort="Caughey, B" uniqKey="Caughey B" first="B." last="Caughey">B. Caughey</name></region><name sortKey="Caughey, B" sort="Caughey, B" uniqKey="Caughey B" first="B." last="Caughey">B. Caughey</name><name sortKey="Caughey, W S" sort="Caughey, W S" uniqKey="Caughey W" first="W. S." last="Caughey">W. S. Caughey</name><name sortKey="Kocisko, D A" sort="Kocisko, D A" uniqKey="Kocisko D" first="D. A." last="Kocisko">D. A. Kocisko</name><name sortKey="Lee, K S" sort="Lee, K S" uniqKey="Lee K" first="K. S." last="Lee">K. S. Lee</name><name sortKey="Morrey, J D" sort="Morrey, J D" uniqKey="Morrey J" first="J. D." last="Morrey">J. D. Morrey</name><name sortKey="Silveira, J R" sort="Silveira, J R" uniqKey="Silveira J" first="J. R." last="Silveira">J. R. Silveira</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D9570AA45CF61601F20362B4B3A0592330E2FCCE
|texte= Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for Anti-TSE Compounds?
}}
| This area was generated with Dilib version V0.6.33. |  |